Literature DB >> 22005599

The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor.

Zeng-Liang Jin1, Nana Gao, Dan Zhou, Mu-Gen Chi, Xue-Mei Yang, Jiang-Ping Xu.   

Abstract

Fructus Akebiae is a traditional Chinese herbal extract that has been used for the treatment of depressive disorders in China. Previous studies demonstrated that Fructus Akebiae extracts (FAE) displayed a potent antidepressant-like activity in animal behavior tests and found that the specific active ingredient from the extracts of Fructus Akebiae is hederagenin. However, the underlying mechanism is unknown. Here we provide evidences that FAE enhances the signaling of central monoamines via inhibition of the reuptake of the extracellular monoamines including serotonin (5-HT), norepinephrine (NE) and dopamine (DA). In rat brain membrane preparations and HEK293 cells transfected with human serotonin transporter (SERT), NE transporter (NET) and DA transporter (DAT), we found that FAE displayed marked affinity to rat and cloned human monoamine transporters in ex vivo and in vitro experiments, using competitive radio ligand binding assay. In uptake assays using rat synaptosomes and transfected cells, FAE was found to significantly inhibit all three monoamine transporters in a dose- and time-dependent manner, with a comparable or better potency to their corresponding specific inhibitors. In contrast, FAE (10 μM), showed no significant affinity to a variety array of receptors tested from CNS. In support of our uptake data, in vivo microdialysis studies showed that administration of FAE (12.6, 25, 50 mg/kg) significantly increased extracellular concentrations of 5-HT, NE and DA in frontal cortex of freely moving rats. Taken together, our current study showed for the first time that FAE is a novel triple inhibitor of monoamine transporters, which may be one the mechanisms of its antidepressant activity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005599     DOI: 10.1016/j.pbb.2011.10.001

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  CTDP-32476: A Promising Agonist Therapy for Treatment of Cocaine Addiction.

Authors:  Zheng-Xiong Xi; Rui Song; Xia Li; Guan-Yi Lu; Xiao-Qing Peng; Yi He; Guo-Hua Bi; Siyuan Peter Sheng; Hong-Ju Yang; Haiying Zhang; Jin Li; Mark Froimowitz; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2016-08-18       Impact factor: 7.853

Review 2.  Psychiatric neural networks and neuropharmacology: Selected advances and novel implications.

Authors:  Abdelaziz Ghanemi
Journal:  Saudi Pharm J       Date:  2013-02-10       Impact factor: 4.330

3.  Preclinical Safety of the Root Extract of Polygala tenuifolia Willdenow in Sprague-Dawley Rats and Beagle Dogs.

Authors:  Ki Young Shin; Beom Young Won; Hyun Jee Ha; Yeo Sang Yun; Hyung Gun Lee
Journal:  Evid Based Complement Alternat Med       Date:  2014-11-05       Impact factor: 2.629

4.  Receptor and transporter binding and activity profiles of albiflorin extracted from Radix paeoniae Alba.

Authors:  Zeng-Liang Jin; Nana Gao; Weizhe Xu; Pingxiang Xu; Shuaiqi Li; Yuan-Yuan Zheng; Ming Xue
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

Review 5.  Translational Informatics for Natural Products as Antidepressant Agents.

Authors:  Rajeev K Singla; Shikha Joon; Li Shen; Bairong Shen
Journal:  Front Cell Dev Biol       Date:  2022-01-20

Review 6.  Current knowledge and development of hederagenin as a promising medicinal agent: a comprehensive review.

Authors:  Jia Zeng; Ting Huang; Man Xue; Jianxing Chen; Linglin Feng; Ruofei Du; Yi Feng
Journal:  RSC Adv       Date:  2018-07-03       Impact factor: 4.036

7.  Effects of Fructus Akebiae on learning and memory impairment in a scopolamine-induced animal model of dementia.

Authors:  Jinghua Wang; Xuan Wang; Baosheng Lv; Weixiu Yuan; Zeguo Feng; Weidong Mi; Hong Zhang
Journal:  Exp Ther Med       Date:  2014-06-11       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.